BAKER BROS. ADVISORS LP
Q1 2014 13F-HR Holdings
Net value change ($000)
+772,196
(10.9%)
New positions
20
Sold out positions
7
Turnover %
3.2%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q4 2013
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| *SYNAGEVA BIOPHARMA CORP | 218,600 | 32.9% |
| INTERMUNE INC | 142,542 | 6449.9% |
| Seagen Inc. | 117,731 | 14.2% |
| INTERCEPT PHARMACEUTICALS, INC. | 59,775 | 241.3% |
| INCY | 44,140 | 5.9% |
| Acorda Therapeutics, Inc. | 37,910 | NEW |
| HRTX | 30,153 | NEW |
| ANACOR PHARMACEUTICALS INC | 19,987 | 47.6% |
| DERMA SCIENCES INC | 17,164 | 62.0% |
| AQUINOX PHARMACEUTICALS INC | 15,427 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| PHARMACYCLICS INC | -46,608 | -5.1% |
| GENOMIC HEALTH INC | -39,910 | -10.0% |
| XOMA | -34,878 | -22.5% |
| MEDIVATION | -25,421 | -100.0% |
| HALO | -22,026 | -23.3% |
| Arrowhead Pharma Inc | -21,507 | -64.1% |
| CERS | -13,952 | -25.6% |
| *AEGERION PHARMACEUTICALS INC | -11,778 | -33.2% |
| Infinity Pharmaceuticals Inc. | -8,883 | -100.0% |
| BMRN | -8,116 | -5.9% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|